Government-Owned Inventions; Availability for Licensing, 64808-64809 [2014-25874]
Download as PDF
<![CDATA[
64808
Federal Register / Vol. 79, No. 211 / Friday, October 31, 2014 / Notices
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
axicon or annular aperture, can provide
extended depth of field.
Potential Commercial Applications:
Resolution enhancement in light
microscopy
Competitive Advantages: Image
composition using processing system
Development Stage:
• Early-stage
• Prototype
Inventors: Hari Shroff (NIBIB), Yicong
Wu (NIBIB), Sara Abrahamsson (The
Rockefeller University)
Intellectual Property: HHS Reference
No. E–232–2014/0—U.S. Provisional
Patent Application 62/054,484 filed
September 24, 2014
Related Technology: HHS Reference
No. E–078–2011/0—
• PCT Application No. PCT/US2012/
27524 filed March 02, 2012
• U.S. Patent Application No. 14/
003,380 filed September 5, 2013, which
published as US 2014–0126046–A1 on
May 08, 2014
Licensing Contact: Michael
Shmilovich, Esq.; 301–435–5019;
shmilovm@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Biomedical
Imaging and Bioengineering is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize light sheet microscopy
image resolution enhancement. For
collaboration opportunities, please
contact Cecilia Pazman at 301–594–
4273 or pazmance@nhlbi.nih.gov.
Resolution Enhancement Technique for
Light Sheet Microscopy Systems
Description of Technology: The
invention pertains to a technique for
enhancing the resolution of a light sheet
microscopy technique by adding an
additional enhanced depth-of-focus
optical arrangement and high numerical
aperture objective lens. The technique
employs an arrangement of three
objective lenses and a processor for
combining captured images from the
objectives. The resulting image
composite retains the greater resolving
power of the third high numerical
aperture objective lens by imaging the
light sheet with the third objective lens
and enhanced depth-of-focus
arrangement so that the overall
resolution of the light sheet system is
improved. The depth of field
arrangement could be a simple
oscillation of the third objective, or a
‘‘layer cake’’ or cubic phase mask
component. Any loss in lateral
resolution that results from the depth of
field arrangement may be compensated
for by deconvolution. In some
embodiments, other optics, such as an
Resolution Enhancement for LineScanning Excitation Microscopy
Description of Technology: The
invention describes a method for
improving the spatial resolution of
optical microscopes that use linescanning excitation, such as linescanning confocal microscopes, linescanning STED microscopes, or linescanning light-sheet microscopes.
Common elements of the invention
include: (a) An apparatus for exciting
and scanning a line-like excitation focus
through the sample; (b) an optical
arrangement on the detection side of the
microscope for manipulating the
spacing and/or width of the resulting
fluorescence emissions; (c) integration
and optional post-processing of the
manipulated fluorescence emissions
after capture by an area detector such as
a camera. The resolution increase may
be performed with no or marginal
decrease in temporal resolution relative
to the conventional line-scanning
microscopes upon which the technique
is based.
Potential Commercial Applications:
Fluorescence microscopy
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:51 Oct 30, 2014
Jkt 235001
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
Competitive Advantages:
• Improved resolution
• Enhanced acquisition speed relative
to other forms of super-resolution
microscopy
Development Stage: Prototype
Inventors: Hari Shroff, Andrew York,
John Giannini, Abhishek Kumar (all of
NIBIB)
Intellectual Property: HHS Reference
No. E–225–2014—U.S. Provisional
Patent Application 62/054,481 filed
September 24, 2014
Licensing Contact: Michael
Shmilovich, Esq.; 301–435–5019;
shmilovm@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Biomedical
Imaging and Bioengineering is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize fluorescent microscopy.
For collaboration opportunities, please
contact Cecilia Pazman at 301–594–
4273 or pazmance@nhlbi.nih.gov.
Chemotherapeutic Anti-Cancer Agents
Description of Technology: Available
for licensing are new compounds
derived from 4-benzyl-amino-benzyl
alcohol. These compounds possess
potent activity in multiple in vitro
models of cancer cell growth inhibition
and in vivo xenograft models of renal
tumor regression. These compounds
could potentially be developed into
promising therapeutic agents for the
treatment of various cancers.
Potential Commercial Applications:
Chemotherapy of cancer
Competitive Advantages:
• Extreme potency for tumor
regression in vivo.
• Compounds with similar profiles
have been approved by the FDA as
chemotherapeutic agents.
—Preliminary toxicology data
available.
Development Stage:
• In vitro data available
• In vivo data available (animal)
Inventors: Joel Morris and Donn
Wishka (NCI)
Intellectual Property: HHS Reference
No. E–027–2014/0—U.S. Application
No. 61/933,606 filed 20 Jan 2014
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560; mccuepat@
od.nih.gov
Novel Codon-Optimized Gene
Therapeutic for Methylmalonic
Acidemia
Description of Technology:
Methylmalonic Acidemia (MMA) is a
metabolic disorder characterized by
increased acidity in the blood and
tissues due to toxic accumulation of
E:\FR\FM\31OCN1.SGM
31OCN1
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 211 / Friday, October 31, 2014 / Notices
protein and fat by-products resulting in
seizures, strokes, and chronic kidney
failure. A significant portion of MMA
cases stem from a deficiency in a key
mitochondrial enzyme, methylmalonylCoA mutase (MUT), required to break
down amino acids and lipids. Currently,
there are no treatments for MMA and
the disease is managed primarily with
dietary restriction of amino acid
precursors and liver-kidney
transplantation in severe cases.
The present invention describes a
synthetic codon-optimized MUT gene
(co-MUT) that improves expression of
human methylmalonyl-CoA mutase. A
series of novel gene therapy vectors
containing co-MUT rescued MMA mice
from lethality and lowered levels of
methylmalonic acid in the blood.
Results of pre-clinical efficacy studies
demonstrate a promising therapy for
MMA and other renal-associated
disorders.
Potential Commercial Applications:
• The co-MUT transgene could be
used to treat MMA patients.
• In addition, it could be used to
produce MUT in vitro for MMA enzyme
replacement therapy.
Competitive Advantages: co-MUT
transgene could be used through nonviral and viral gene delivery.
Development Stage:
• In vitro data available
• In vivo data available (animal)
Inventors: Charles P. Venditti and
Randy J. Chandler (NHGRI)
Intellectual Property: HHS Reference
No. E–243–2012/0—
• U.S. Provisional Application No.
61/792,081 filed 15 March 2013
• PCT Application No. PCT/US2014/
028045 filed 14 March 2014
Licensing Contact: Vince Contreras,
Ph.D.; 301–435–4711; vince.contreras@
nih.gov
Collaborative Research Opportunity:
The Organic Acid Research Section at
the National Human Genome Research
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize codon-optimized MUT
constructs. For collaboration
opportunities, please contact Claire T.
Driscoll at cdriscoll@mail.nih.gov.
Dated: October 28, 2014.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2014–25874 Filed 10–30–14; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HOMELAND
SECURITY
National Institutes of Health
Office of the Secretary
National Institute of Environmental
Health Sciences; Notice of Closed
Meeting
[Docket No. DHS–2014–0053]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Review of NIEHS R13
Conference Grant Applications.
Date: November 24, 2014.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building,
Conference Room 3118, 530 Davis Drive,
Research Triangle Park, NC 27709,
(Telephone Conference Call).
Contact Person: Janice B. Allen, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute of Environmental
Health Science, P.O. Box 12233, MD EC–30/
Room 3170 B, Research Triangle Park, NC
27709, 919/541–7556.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: October 24, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–25873 Filed 10–30–14; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:51 Oct 30, 2014
Jkt 235001
64809
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Privacy Act of 1974; Department of
Homeland Security/United States
Coast Guard—010 Physical Disability
Evaluation System Files System of
Records
Privacy Office, Department of
Homeland Security.
ACTION: Notice of Privacy Act System of
Records.
AGENCY:
In accordance with the
Privacy Act of 1974, the Department of
Homeland Security proposes to update
and reissue a current Department of
Homeland Security system of records
titled, ‘‘Department of Homeland
Security/United States Coast Guard
Physical Disability Evaluation System
Files System of Records.’’ This system
of records allows the Department of
Homeland Security/United States Coast
Guard to collect and preserve the
records regarding physical disability
evaluation proceedings. As a result of
the biennial review of this system, the
system manager and address category
has been updated. This updated system
will be included in the Department of
Homeland Security’s inventory of
record systems.
DATES: Submit comments on or before
December 1, 2014. This updated system
will be effective December 1, 2014.
ADDRESSES: You may submit comments,
identified by docket number DHS–
2014–0053 by one of the following
methods:
• Federal e-Rulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Fax: 202–343–4010.
• Mail: Karen L. Neuman, Chief
Privacy Officer, Privacy Office,
Department of Homeland Security,
Washington, DC 20528.
Instructions: All submissions received
must include the agency name and
docket number for this rulemaking. All
comments received will be posted
without change to https://
www.regulations.gov, including any
personal information provided.
Docket: For access to the docket to
read background documents or
comments received, please visit https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: For
general questions, please contact:
Marilyn Scott-Perez (202–475–3515),
Privacy Officer, Commandant (CG–61),
United States Coast Guard, Mail Stop
SUMMARY:
E:\FR\FM\31OCN1.SGM
31OCN1
]]>Agencies
[Federal Register Volume 79, Number 211 (Friday, October 31, 2014)]
[Notices]
[Pages 64808-64809]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-25874]
[[Page 64808]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Resolution Enhancement Technique for Light Sheet Microscopy Systems
Description of Technology: The invention pertains to a technique
for enhancing the resolution of a light sheet microscopy technique by
adding an additional enhanced depth-of-focus optical arrangement and
high numerical aperture objective lens. The technique employs an
arrangement of three objective lenses and a processor for combining
captured images from the objectives. The resulting image composite
retains the greater resolving power of the third high numerical
aperture objective lens by imaging the light sheet with the third
objective lens and enhanced depth-of-focus arrangement so that the
overall resolution of the light sheet system is improved. The depth of
field arrangement could be a simple oscillation of the third objective,
or a ``layer cake'' or cubic phase mask component. Any loss in lateral
resolution that results from the depth of field arrangement may be
compensated for by deconvolution. In some embodiments, other optics,
such as an axicon or annular aperture, can provide extended depth of
field.
Potential Commercial Applications: Resolution enhancement in light
microscopy
Competitive Advantages: Image composition using processing system
Development Stage:
Early-stage
Prototype
Inventors: Hari Shroff (NIBIB), Yicong Wu (NIBIB), Sara Abrahamsson
(The Rockefeller University)
Intellectual Property: HHS Reference No. E-232-2014/0--U.S.
Provisional Patent Application 62/054,484 filed September 24, 2014
Related Technology: HHS Reference No. E-078-2011/0--
PCT Application No. PCT/US2012/27524 filed March 02, 2012
U.S. Patent Application No. 14/003,380 filed September 5,
2013, which published as US 2014-0126046-A1 on May 08, 2014
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
shmilovm@mail.nih.gov
Collaborative Research Opportunity: The National Institute of
Biomedical Imaging and Bioengineering is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize light sheet
microscopy image resolution enhancement. For collaboration
opportunities, please contact Cecilia Pazman at 301-594-4273 or
pazmance@nhlbi.nih.gov.
Resolution Enhancement for Line-Scanning Excitation Microscopy
Description of Technology: The invention describes a method for
improving the spatial resolution of optical microscopes that use line-
scanning excitation, such as line-scanning confocal microscopes, line-
scanning STED microscopes, or line-scanning light-sheet microscopes.
Common elements of the invention include: (a) An apparatus for exciting
and scanning a line-like excitation focus through the sample; (b) an
optical arrangement on the detection side of the microscope for
manipulating the spacing and/or width of the resulting fluorescence
emissions; (c) integration and optional post-processing of the
manipulated fluorescence emissions after capture by an area detector
such as a camera. The resolution increase may be performed with no or
marginal decrease in temporal resolution relative to the conventional
line-scanning microscopes upon which the technique is based.
Potential Commercial Applications: Fluorescence microscopy
Competitive Advantages:
Improved resolution
Enhanced acquisition speed relative to other forms of
super-resolution microscopy
Development Stage: Prototype
Inventors: Hari Shroff, Andrew York, John Giannini, Abhishek Kumar
(all of NIBIB)
Intellectual Property: HHS Reference No. E-225-2014--U.S.
Provisional Patent Application 62/054,481 filed September 24, 2014
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
shmilovm@mail.nih.gov
Collaborative Research Opportunity: The National Institute of
Biomedical Imaging and Bioengineering is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize fluorescent
microscopy. For collaboration opportunities, please contact Cecilia
Pazman at 301-594-4273 or pazmance@nhlbi.nih.gov.
Chemotherapeutic Anti-Cancer Agents
Description of Technology: Available for licensing are new
compounds derived from 4-benzyl-amino-benzyl alcohol. These compounds
possess potent activity in multiple in vitro models of cancer cell
growth inhibition and in vivo xenograft models of renal tumor
regression. These compounds could potentially be developed into
promising therapeutic agents for the treatment of various cancers.
Potential Commercial Applications: Chemotherapy of cancer
Competitive Advantages:
Extreme potency for tumor regression in vivo.
Compounds with similar profiles have been approved by the
FDA as chemotherapeutic agents.
--Preliminary toxicology data available.
Development Stage:
In vitro data available
In vivo data available (animal)
Inventors: Joel Morris and Donn Wishka (NCI)
Intellectual Property: HHS Reference No. E-027-2014/0--U.S.
Application No. 61/933,606 filed 20 Jan 2014
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
mccuepat@od.nih.gov
Novel Codon-Optimized Gene Therapeutic for Methylmalonic Acidemia
Description of Technology: Methylmalonic Acidemia (MMA) is a
metabolic disorder characterized by increased acidity in the blood and
tissues due to toxic accumulation of
[[Page 64809]]
protein and fat by-products resulting in seizures, strokes, and chronic
kidney failure. A significant portion of MMA cases stem from a
deficiency in a key mitochondrial enzyme, methylmalonyl-CoA mutase
(MUT), required to break down amino acids and lipids. Currently, there
are no treatments for MMA and the disease is managed primarily with
dietary restriction of amino acid precursors and liver-kidney
transplantation in severe cases.
The present invention describes a synthetic codon-optimized MUT
gene (co-MUT) that improves expression of human methylmalonyl-CoA
mutase. A series of novel gene therapy vectors containing co-MUT
rescued MMA mice from lethality and lowered levels of methylmalonic
acid in the blood. Results of pre-clinical efficacy studies demonstrate
a promising therapy for MMA and other renal-associated disorders.
Potential Commercial Applications:
The co-MUT transgene could be used to treat MMA patients.
In addition, it could be used to produce MUT in vitro for
MMA enzyme replacement therapy.
Competitive Advantages: co-MUT transgene could be used through non-
viral and viral gene delivery.
Development Stage:
In vitro data available
In vivo data available (animal)
Inventors: Charles P. Venditti and Randy J. Chandler (NHGRI)
Intellectual Property: HHS Reference No. E-243-2012/0--
U.S. Provisional Application No. 61/792,081 filed 15 March
2013
PCT Application No. PCT/US2014/028045 filed 14 March 2014
Licensing Contact: Vince Contreras, Ph.D.; 301-435-4711;
vince.contreras@nih.gov
Collaborative Research Opportunity: The Organic Acid Research
Section at the National Human Genome Research Institute is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate or commercialize
codon-optimized MUT constructs. For collaboration opportunities, please
contact Claire T. Driscoll at cdriscoll@mail.nih.gov.
Dated: October 28, 2014.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2014-25874 Filed 10-30-14; 8:45 am]
BILLING CODE 4140-01-P
